Previous studies demonstrated high SUZ12 expression levels in aggressive tumors, such as prostatic carcinoma (9), breast carcinoma (10) and nervous system carcinoma (11), and a marked correlation between SUZ12 expression levels and tumor malignancy. This evidence concerns the gene SUZ12 and breast carcinoma.